ACKSONVILLE, Florida, September 6, 2016, TPIV, /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today issued a shareholder update regarding significant recent financial, clinical and regulatory milestones achieved, as well as an outlook on future catalysts. Dear Shareholders: We believe recent events have been transformative for TapImmune. We believe we are now funded to execute on the 4 PhaseRead more
- Sack Lunch Productions Reduces Debt by an Estimated $2M in Q1
- American Premium Water Corporation (OTC Pink: HIPH) Announces International Distribution Agreement
- Pura Naturals Showcases Pura Marine Products at the 72nd Annual Fred Hall Show in Long Beach, CA
- Marijuana Company of America Announces the Offical Launch of Benihemp at the ASD Trade Show
- American Cannabis Company, Inc. Secures New Online Distribution Channels with Walmart, The Home Depot and Amazon for SoHum Living Soils and Dr. Marijane Root Probiotic
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More